Emedgene, the world’s first completely automated genetic interpretation platform, announced that it raised $6 million in a funding round led by OliveTree Ventures to scale genomics-based care with artificial intelligence (AI).
Emedgene provides solutions that interpret genetic tests automatically, helping geneticists manage workloads faster and with higher accuracy. This is achieved with an AI engine that has learned to perform genomics research, after training with millions of data points from patient cases, databases, and the most recent genomics publications, Emedgene says.
“Personal, genetics-based medicine is poised to be the next revolution in patient care. Genetic testing is advancing at breakthrough speed, with tens of thousands of new findings published every year, and millions of additional tests performed,” says Einat Metzer, Emedgene’s CEO.
“This rise in genomics-based medicine is putting tremendous pressure on geneticists globally – who must analyze and interpret each test. It is a costly, labor-intensive process that is the main bottleneck to growth,” she adds.
Its support platform can pinpoint causative genetic variants in diverse applications such as rare disease identification, healthy population screening, carrier screening, and pharmacogenomics. Using Emedgene, the company says, health organizations can improve patient outcomes by offering personalized care throughout a patient’s life.
Emedgene is being used by leading health organizations including Israel’s MoH 100K Genome Project.
“Genetic testing and discovery are clearly undergoing rapid growth, and Emedgene has a game-changing solution rooted in a combination of technology and science. We’re excited to support the team in making personalized care a reality,” says Amir Lahat, General Partner at Olive Tree Ventures.
Emedgene says it will use the funds to expand sales operations in the US.